$986 Million is the total value of BVF INC/IL's 43 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 38.1% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CCXI | Sell | CHEMOCENTRYX INC | $97,938,000 | +116.9% | 7,201,316 | -5.1% | 9.93% | +82.4% |
| ARRY | Sell | ARRAY BIOPHARMA INC | $82,624,000 | -25.7% | 5,062,768 | -41.7% | 8.38% | -37.5% |
| BPMC | Sell | BLUEPRINT MEDICINES CORP | $60,120,000 | +3.9% | 655,611 | -14.6% | 6.09% | -12.6% |
| CNCE | Sell | CONCERT PHARMACEUTICALS INC | $44,246,000 | -13.2% | 1,932,123 | -1.9% | 4.48% | -27.0% |
| ANAB | Sell | ANAPTYSBIO INC | $40,182,000 | -32.9% | 386,065 | -35.0% | 4.07% | -43.6% |
| CTIC | Sell | CTI BIOPHARMA CORP | $27,026,000 | +17.3% | 6,929,690 | -19.4% | 2.74% | -1.3% |
| OMED | Sell | ONCOMED PHARMACEUTICALS INC | $13,525,000 | -22.8% | 4,253,189 | -0.4% | 1.37% | -35.1% |
| GTXI | Sell | GTX INC DEL | $10,823,000 | -23.1% | 609,748 | -44.9% | 1.10% | -35.4% |
| TOCA | Sell | TOCAGEN INC | $5,978,000 | +4.8% | 504,483 | -9.4% | 0.61% | -11.9% |
| MTEM | Sell | MOLECULAR TEMPLATES INC | $5,509,000 | -24.1% | 688,629 | -4.9% | 0.56% | -36.2% |
| SNSS | Sell | SUNESIS PHARMACEUTICALS INC | $4,582,000 | -39.2% | 1,684,636 | -17.5% | 0.46% | -49.0% |
| XENE | Sell | XENON PHARMACEUTICALS INC | $3,532,000 | -65.2% | 720,830 | -79.9% | 0.36% | -70.7% |
| OREXQ | Sell | OREXIGEN THERAPEUTICS INC | $108,000 | -88.6% | 534,900 | -27.2% | 0.01% | -90.4% |
| PTIE | Exit | PAIN THERAPEUTICS INC | $0 | – | -325,509 | -100.0% | -0.16% | – |
| ANTH | Exit | ANTHERA PHARMACEUTICALS INC | $0 | – | -1,216,403 | -100.0% | -0.24% | – |
| Exit | OREXIGEN THERAPEUTICS INCnote 2.750%12/0 | $0 | – | -10,000,000 | -100.0% | -0.43% | – | |
| ITCI | Exit | INTRA CELLULAR THERAPIES INC | $0 | – | -273,350 | -100.0% | -0.48% | – |
| ACHN | Exit | ACHILLION PHARMACEUTICALS INC | $0 | – | -1,608,433 | -100.0% | -0.56% | – |
| GLYC | Exit | GLYCOMIMETICS INC | $0 | – | -497,474 | -100.0% | -1.01% | – |
| CASC | Exit | CASCADIAN THERAPEUTICS INC | $0 | – | -3,133,224 | -100.0% | -1.40% | – |
| CTMX | Exit | CYTOMX THERAPEUTICS INC | $0 | – | -1,124,483 | -100.0% | -2.86% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-05-07
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 37 | Q4 2023 | 4.7% |
| PIERIS PHARMACEUTICALS INC | 32 | Q1 2024 | 2.8% |
| XOMA CORP DEL | 31 | Q2 2024 | 7.3% |
| CYTOKINETICS INC | 29 | Q4 2020 | 11.8% |
| INFINITY PHARMACEUTICALS INC | 29 | Q2 2023 | 4.3% |
| CYTOMX THERAPEUTICS INC | 29 | Q2 2024 | 5.3% |
| KURA ONCOLOGY INC | 28 | Q2 2024 | 5.1% |
| CORVUS PHARMACEUTICALS INC | 28 | Q1 2024 | 2.3% |
| ARQULE INC | 27 | Q4 2019 | 4.8% |
| GLYCOMIMETICS INC | 27 | Q2 2024 | 5.7% |
View BVF INC/IL's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| N-PX | 2024-09-03 |
| 4 | 2024-08-22 |
| 13F-HR | 2024-08-14 |
| 3 | 2024-08-01 |
| 4 | 2024-06-28 |
| 4 | 2024-06-18 |
| 4 | 2024-06-10 |
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-13 |
| 13F-HR | 2024-02-14 |
View BVF INC/IL's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.